Catheter Ablation for Ventricular Tachycardia in HCM: Electrophysiological Characteristics and Long-Term Outcomes
Authors, Journal, Affiliations, Type, DOI
- Authors: Shuyu Jin, Mengmeng Li, Chenxi Jiang, Ribo Tang, Caihua Sang, Wei Wang, Xin Zhao, Changyi Li, Songnan Li, Xueyuan Guo, Changqi Jia, Man Ning, Li Feng, Dan Wen, Hui Zhu, Tong Liu, Yuexin Jiang, Fang Liu, Chao Jiang, Ning Zhou, Kangning Han, Jie Yang, Deyong Long, Xin Du, Jianzeng Dong, Changsheng Ma
- Journal: JACC: Clinical Electrophysiology 2025;11(10):2151–2164
- Affiliations: Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center for Cardiovascular Diseases (Beijing); The First Affiliated Hospital of Zhengzhou University (Zhengzhou, Henan)
- Type: Retrospective single-centre cohort study (December 2014 to August 2023)
- DOI: 10.1016/j.jacep.2025.05.028
Overview
This is the largest reported cohort of catheter ablation for hypertrophic cardiomyopathy–related ventricular tachycardia, with combined endocardial and epicardial mapping in 29 of 32 patients. The study shows that HCM-related ventricular tachycardia is usually a three-dimensional re-entrant circuit with mid-myocardial involvement, and that the distribution of the circuit determines outcome: the left ventricular lateral wall and apical aneurysm respond well, whereas the superior basal region and interventricular septum respond poorly. The findings argue for combined endocardial-epicardial mapping and site-specific ablation strategies rather than a uniform approach.
Keywords
Catheter ablation; Hypertrophic cardiomyopathy; Three-dimensional re-entrant circuits; Ventricular tachycardia
Key Takeaways
Study design and population
- Thirty-two consecutive patients with hypertrophic cardiomyopathy and ventricular tachycardia who underwent ablation at Beijing Anzhen Hospital between December 2014 and August 2023.
- Mean age 56.5 ± 12.4 years; 27 men (87.1%); mean left ventricular ejection fraction 49.9% ± 12.2%; mean left ventricular end-diastolic diameter 53.5 ± 5.8 mm; mean interventricular septum thickness 16.8 ± 3.9 mm; no patient had resting left ventricular outflow tract obstruction.
- Eight patients (25.0%) had a left ventricular apical aneurysm; 10 (31.3%) had an implantable cardioverter-defibrillator before the index procedure; 5 (15.6%) had prior ventricular tachycardia ablation; 1 had left cardiac sympathetic denervation.
- Patients with left ventricular end-diastolic diameter ≥60 mm were excluded to avoid overlap with dilated cardiomyopathy.
Mapping and substrate distribution
- Combined endocardial and epicardial mapping was performed in 29 of 32 patients (90.6%); three patients had endocardial mapping only because a septal or papillary muscle origin was suspected.
- Twenty-eight ventricular tachycardias were induced and mapped in 25 patients: 25 were scar-mediated re-entries, 2 were focal, and 1 was bundle branch re-entry.
- Re-entry distribution: left ventricular lateral wall 15 (46.9%), apical aneurysm 6 (18.8%), superior basal region 6 (18.8%), left posterior papillary muscle 3 (9.4%), interventricular septum 1 (3.1%), and His-Purkinje system 1 (3.1%).
- All scar-mediated re-entrant circuits had a three-dimensional pattern with mid-myocardial involvement: incomplete endocardial re-entry 17.9%, incomplete epicardial re-entry 28.6%, transmural re-entry 14.3%, and exclusive mid-myocardial re-entry 28.6%.
- Site-specific patterns: the lateral wall showed incomplete epicardial re-entry in 77.8%; the apical aneurysm showed transmural re-entry in 66.7%; the superior basal region showed exclusive mid-myocardial re-entry in 87.5%; the single septal circuit showed exclusive mid-myocardial re-entry.
- Low-voltage areas were present at both endocardial and epicardial surfaces in 9 patients, epicardium only in 13, endocardium only in 1, and no definite scar in 6. The epicardial low-voltage area was larger than the endocardial area at the apical aneurysm (66.3 ± 33.9 vs 22.7 ± 17.5 cm²; P = 0.008).
Ablation strategy and acute results
- Substrate and activation mapping were combined; ablation targeted the critical isthmus. For septal VT near the His bundle, energy was started at 10–15 W and titrated to 25 W with junctional monitoring; non-septal sites used 35–45 W with irrigation.
- Acute success, defined as elimination of local abnormal ventricular activities and no inducible clinical VT, was achieved in 28 of 32 patients (87.5%).
- Acute success by site: lateral wall 15/15 (100%), apical aneurysm 6/6 (100%), superior basal region 3/6 (50%), interventricular septum 0/1 (0%), papillary muscle 3/3 (100%), His-Purkinje 1/1 (100%).
- Mean procedural duration was 127.4 ± 57.9 minutes; mean ablation duration was 20.8 ± 15.7 minutes.
Long-term outcomes
- After a median follow-up of 31 months (range 11–115 months), long-term success after the index procedure was 73.3% for lateral wall VT, 83.3% for apical aneurysm VT, 0% for superior basal VT, 0% for septal VT, 100% for papillary muscle VT, and 100% for His-Purkinje VT.
- After multiple procedures, the overall success rate was 71.9%; five patients underwent repeat ablation, mostly at the same site.
- Two patients died during follow-up: one from cancer without recurrent VT and one from unknown causes.
- No significant progression of the low-voltage area was observed between the index and repeat procedures.
Interpretation
- HCM-related VT is predominantly a three-dimensional re-entrant circuit with mid-myocardial involvement; the extent of intramural involvement varies by region and determines procedural success.
- The lateral wall and apical aneurysm are the most favourable targets; the superior basal region and septum are the least favourable because the circuit is largely intramural and difficult to reach with endocardial radiofrequency.
- Combined endocardial-epicardial mapping and ablation are recommended, particularly for lateral wall and apical aneurysm circuits; advanced intramural techniques may be needed for superior basal and septal circuits.
Limitations of the document
- Retrospective, single-centre design with a relatively small sample (32 patients); generalisability is limited.
- Exclusion of left ventricular end-diastolic diameter ≥60 mm limits applicability to end-stage/dilated-phase hypertrophic cardiomyopathy.
- Activation mapping was not performed in every case because of haemodynamic instability or non-inducibility, so some circuits could not be fully delineated.
- Advanced intramural mapping and ablation techniques (needle ablation, bipolar radiofrequency, alcohol ablation) were not used, which may have limited success in superior basal and septal circuits.
- Cardiac magnetic resonance was not obtained in all patients because of implanted devices and patient factors; genetic testing was not available for all.
- Single-centre operator experience and evolving technology may affect reproducibility.
Key Concepts Mentioned
- concepts/VT-in-HCM — the HCM-specific VT substrate and ablation outcomes
- concepts/VT-Ablation — the general procedural framework
- concepts/Epicardial-VT-Ablation — the epicardial approach
- concepts/Late-Gadolinium-Enhancement — scar imaging
- entities/HCM — the underlying cardiomyopathy
- entities/ICD — device therapy
Key Entities Mentioned
- Hypertrophic cardiomyopathy
- Apical aneurysm
- Left ventricular lateral wall
- Interventricular septum
- Papillary muscle
Wiki Pages Updated
- Created:
wiki/sources/hcm-vt-ablation-jacep-2025.md - Updated:
wiki/concepts/VT-in-HCM.md - Updated:
wiki/entities/HCM.md - Updated:
wiki/concepts/HCM-Management.md - Updated:
wiki/concepts/VT-Ablation.md - Updated:
wiki/sourceindex.md - Updated:
wiki/wikiindex.md - Updated:
log.md